9,630 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by Sciencast Management LP

Sciencast Management LP purchased a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 9,630 shares of the medical equipment provider's stock, valued at approximately $694,000.

Several other large investors have also made changes to their positions in HOLX. General Partner Inc. bought a new position in Hologic during the fourth quarter valued at about $26,000. Venturi Wealth Management LLC boosted its stake in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 261 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after acquiring an additional 134 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its holdings in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Analyst Ratings Changes

HOLX has been the topic of several analyst reports. Stephens reiterated an "overweight" rating and set a $84.00 price target on shares of Hologic in a report on Thursday, February 6th. Raymond James reiterated an "outperform" rating and issued a $90.00 target price (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Jefferies Financial Group initiated coverage on shares of Hologic in a report on Tuesday, December 10th. They set a "hold" rating and a $85.00 price target for the company. Morgan Stanley dropped their price objective on Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Finally, Wolfe Research began coverage on Hologic in a research note on Friday, December 13th. They set a "peer perform" rating for the company. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Hologic currently has an average rating of "Hold" and a consensus target price of $84.62.

Remove Ads

Hologic Price Performance

Shares of HOLX stock traded up $0.84 during mid-day trading on Thursday, reaching $62.32. The company's stock had a trading volume of 1,303,646 shares, compared to its average volume of 1,751,573. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The firm's 50-day moving average is $65.56 and its two-hundred day moving average is $73.57. Hologic, Inc. has a 1-year low of $60.34 and a 1-year high of $84.67. The company has a market cap of $13.98 billion, a P/E ratio of 19.66, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.